Financings in Brief: Oxis International
This article was originally published in The Gray Sheet
Oxis International: Raises $2,037,836 through private placement of 1,227,625 shares of common to Canadian and European investors. The Portland, Oregon diagnostics and drug developer will use the funds for R&D and marketing programs. The firm separately announced FDA marketing clearance of its Beta Lactamase Rapid Enzyme Detection Discs, which are used to "detect the production of the beta lactamase enzyme by certain antibiotic-resistant bacteria that cause infections." Marketing is expected to commence "as early as" the fourth quarter of 1995...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.